Genmab's DARZALEX Royalties Surge on Record Q2 Sales
Event summary
- Genmab reported USD 4.207 billion in worldwide net sales of DARZALEX for Q2 2026, up from previous quarters
- U.S. sales accounted for USD 2.435 billion, with the rest of the world contributing USD 1.772 billion
- Royalties are earned under an exclusive license agreement with Johnson & Johnson (J&J)
- Sales include both intravenous and subcutaneous formulations of daratumumab
The big picture
Genmab's strong Q2 performance underscores the continued dominance of DARZALEX in the multiple myeloma treatment landscape. The biotech company's reliance on royalty income from J&J highlights both its financial leverage and potential vulnerability to shifts in commercialization strategies or competitive pressures. As antibody therapies gain broader adoption, Genmab's ability to diversify its pipeline will be critical for long-term growth.
What we're watching
- Market Expansion
- Whether Genmab can sustain this growth pace as DARZALEX faces potential biosimilar competition post-patent expiry.
- Pipeline Development
- How Genmab's late-stage clinical pipeline will impact future royalty streams beyond DARZALEX.
- Partnership Dynamics
- The evolving relationship with J&J as the primary commercialization partner for daratumumab.
Related topics